Beat the Press

Beat the press por Dean Baker

Beat the Press is Dean Baker's commentary on economic reporting. He is a Senior Economist at the Center for Economic and Policy Research (CEPR). To never miss a post, subscribe to a weekly email roundup of Beat the Press. Please also consider supporting the blog on Patreon.

The idea that the United States is involved in an intense global rivalry with China has gained serious credence among elite types. This is both wrong and dangerous.
The idea that the United States is involved in an intense global rivalry with China has gained serious credence among elite types. This is both wrong and dangerous.
There is a great interest in pretending the story is complicated to excuse such an enormous policy failure.
There is a great interest in pretending the story is complicated to excuse such an enormous policy failure.
Most of the discussion is quite good, but one item that raised my eyebrow was in the section on deficits.
Most of the discussion is quite good, but one item that raised my eyebrow was in the section on deficits.
Of course that would be having open research that was freely shared.
Of course that would be having open research that was freely shared.
The Washington Post's fact-checker gave the Biden campaign four Pinocchios, saying that Trump has always promised to protect Social Security.
The Washington Post's fact-checker gave the Biden campaign four Pinocchios, saying that Trump has always promised to protect Social Security.
It was not the natural forces of globalization and technology that made the less-educated big losers, it was how we structured these forces.
It was not the natural forces of globalization and technology that made the less-educated big losers, it was how we structured these forces.
Japan is a huge embarrassment for the deficit hawks.
Japan is a huge embarrassment for the deficit hawks.
This simple and important question does not get anywhere near the attention it deserves.
This simple and important question does not get anywhere near the attention it deserves.
Yep, that's its big story for the day, although people probably saw the number $62 million in the headline.
Yep, that's its big story for the day, although people probably saw the number $62 million in the headline.

Donald Trump’s re-election campaign has been touting that he is tough on the drug companies, unlike the wimpy Joe Biden. Perhaps in Trumpland this is true, but not in the real world. Spending on prescription drugs has actually increased somewhat more rapidly under Trump than Obama-Biden, rising at a 6.3 percent annual rate under Trump compared to a 5.5 percent rate under Obama-Biden.

Here’s the picture showing year over year increases.

As can be seen, spending grew relatively slowly through Obama’s first term, hitting a low of just 1.9 percent in the first quarter of 2013. It then sped up over the next year before downward again at the start of 2015. In the last quarter of the administration, the fourth quarter of 2016, spending rose by 3.3 percent.

The general direction in the Trump years has been upward, with a peak of 9.7 percent in the first quarter of 2020, then a drop to 4.4 percent in the second quarter. This falloff is a direct result of the pandemic, as many people put off doctors’ visits, which meant that they would be prescribed fewer drugs. So, before the pandemic, drug spending was rising at a rapid and accelerating pace.

These data are taken from the Bureau of Economic Analysis, National Income and Product Accounts, Table 2.4.5U, Line 121.

Donald Trump’s re-election campaign has been touting that he is tough on the drug companies, unlike the wimpy Joe Biden. Perhaps in Trumpland this is true, but not in the real world. Spending on prescription drugs has actually increased somewhat more rapidly under Trump than Obama-Biden, rising at a 6.3 percent annual rate under Trump compared to a 5.5 percent rate under Obama-Biden.

Here’s the picture showing year over year increases.

As can be seen, spending grew relatively slowly through Obama’s first term, hitting a low of just 1.9 percent in the first quarter of 2013. It then sped up over the next year before downward again at the start of 2015. In the last quarter of the administration, the fourth quarter of 2016, spending rose by 3.3 percent.

The general direction in the Trump years has been upward, with a peak of 9.7 percent in the first quarter of 2020, then a drop to 4.4 percent in the second quarter. This falloff is a direct result of the pandemic, as many people put off doctors’ visits, which meant that they would be prescribed fewer drugs. So, before the pandemic, drug spending was rising at a rapid and accelerating pace.

These data are taken from the Bureau of Economic Analysis, National Income and Product Accounts, Table 2.4.5U, Line 121.

Want to search in the archives?

¿Quieres buscar en los archivos?

Click Here Haga clic aquí